TY - JOUR
T1 - Endoscopic Lung Volume Reduction
T2 - Review of the EMPROVE and LIBERATE trials
AU - Nada, Khaled M.
AU - Nishi, Shawn
N1 - Publisher Copyright:
© 2020 Mayo Foundation for Medical Education and Research
PY - 2021/2
Y1 - 2021/2
N2 - Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.
AB - Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.
UR - http://www.scopus.com/inward/record.url?scp=85164061499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164061499&partnerID=8YFLogxK
U2 - 10.1016/j.mayocpiqo.2020.09.009
DO - 10.1016/j.mayocpiqo.2020.09.009
M3 - Review article
AN - SCOPUS:85164061499
SN - 2542-4548
VL - 5
SP - 177
EP - 186
JO - Mayo Clinic Proceedings: Innovations, Quality and Outcomes
JF - Mayo Clinic Proceedings: Innovations, Quality and Outcomes
IS - 1
ER -